Stereotactic body radiotherapy with CyberKnife^® System for low- and intermediate-risk prostate cancer: clinical outcomes and toxicities of CyPro Trial.

ABSTRACT:

Simple summary

Stereotactic body radiotherapy (SBRT) of 35-36.25 Gy in five fractions with the CyberKnife System yields excellent control with low toxicity in low-intermediate-risk prostate cancer patients. We found no differences in biochemical control and overall survival in relation to dose. There were no significant differences in toxicity or quality of life between the two groups.

Aims

Stereotactic body radiotherapy (SBRT) is an emerging therapeutic approach for low- and intermediate-risk prostate cancer. We present retrospective data on biochemical control, toxicity, and quality of life of CyPro Trial.

Materials and methods

A total of 122 patients with low- and intermediate-risk prostate cancer were treated with the CyberKnife System at a dose of 35 Gy or 36.25

SUBMITTER: Borzillo V 

PROVIDER: S-EPMC10660677 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature